Correlation Between Microbix Biosystems and Theratechnologies

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Microbix Biosystems and Theratechnologies at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Microbix Biosystems and Theratechnologies into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Microbix Biosystems and Theratechnologies, you can compare the effects of market volatilities on Microbix Biosystems and Theratechnologies and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Microbix Biosystems with a short position of Theratechnologies. Check out your portfolio center. Please also check ongoing floating volatility patterns of Microbix Biosystems and Theratechnologies.

Diversification Opportunities for Microbix Biosystems and Theratechnologies

-0.08
  Correlation Coefficient

Good diversification

The 3 months correlation between Microbix and Theratechnologies is -0.08. Overlapping area represents the amount of risk that can be diversified away by holding Microbix Biosystems and Theratechnologies in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Theratechnologies and Microbix Biosystems is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Microbix Biosystems are associated (or correlated) with Theratechnologies. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Theratechnologies has no effect on the direction of Microbix Biosystems i.e., Microbix Biosystems and Theratechnologies go up and down completely randomly.

Pair Corralation between Microbix Biosystems and Theratechnologies

Assuming the 90 days trading horizon Microbix Biosystems is expected to under-perform the Theratechnologies. But the stock apears to be less risky and, when comparing its historical volatility, Microbix Biosystems is 1.68 times less risky than Theratechnologies. The stock trades about -0.08 of its potential returns per unit of risk. The Theratechnologies is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  391.00  in Theratechnologies on April 24, 2025 and sell it today you would earn a total of  38.00  from holding Theratechnologies or generate 9.72% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy98.41%
ValuesDaily Returns

Microbix Biosystems  vs.  Theratechnologies

 Performance 
       Timeline  
Microbix Biosystems 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Microbix Biosystems has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in August 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Theratechnologies 

Risk-Adjusted Performance

Insignificant

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Theratechnologies are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Theratechnologies displayed solid returns over the last few months and may actually be approaching a breakup point.

Microbix Biosystems and Theratechnologies Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Microbix Biosystems and Theratechnologies

The main advantage of trading using opposite Microbix Biosystems and Theratechnologies positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Microbix Biosystems position performs unexpectedly, Theratechnologies can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Theratechnologies will offset losses from the drop in Theratechnologies' long position.
The idea behind Microbix Biosystems and Theratechnologies pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Other Complementary Tools

Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance